We are live on
!
Find out more
CP
Caligan Partners Portfolio holdings
AUM
$1.5B
1-Year Est. Return
518.95%
This Fund
S&P 500
This Quarter
Est. Return
+18.49%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$81.8M
(+28%)
Cap. Flow
+$37.2M
Cap. Flow
% of AUM
9.83%
Top 10 Holdings %
Top 10 Hldgs %
98.61%
Holding
15
New
4
Increased
5
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$19.3M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$11.4M |
| 3 |
Anika Therapeutics
ANIK
|
+$8.58M |
| 4 |
Evolus
EOLS
|
+$7.42M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$4.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Standard BioTools
LAB
|
+$15.6M |
| 2 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$6.22M |
| 3 |
ADMA Biologics
ADMA
|
+$2.14M |
| 4 |
SCTL
Societal CDMO, Inc. Common Stock
SCTL
|
+$592K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Liquidia Corp
LQDA
$7.72B
| $153M | 40.4% |
10,360,945
| – | – |
|
|
ALIM
2
DELISTED
Alimera Sciences
ALIM
| $65.7M | 17.36% |
16,835,154
| – | – |
|
|
3
Anika Therapeutics
ANIK
$202M
| $36.5M | 9.64% |
1,435,993
+354,633
| +33% | +$8.58M |
|
|
4
Evolus
EOLS
$410M
| $26.4M | 6.99% |
1,888,881
+571,025
| +43% | +$7.42M |
|
5
Exelixis
EXEL
$14.2B
| $26.1M | 6.9% |
1,100,730
+190,000
| +21% | +$4.22M |
|
|
VRNA
6
DELISTED
Verona Pharma
VRNA
| $20.9M | 5.51% |
1,296,447
+1,113,383
| +608% | +$19.3M |
|
|
7
Enanta Pharmaceuticals
ENTA
$367M
| $15M | 3.96% |
+858,070
| New | +$11.4M |
|
8
Agios Pharmaceuticals
AGIO
$2.14B
| $14.2M | 3.75% |
484,711
+42,878
| +10% | +$1.15M |
|
|
YMAB
9
DELISTED
Y-mAbs Therapeutics
YMAB
| $9.55M | 2.52% |
587,276
-461,149
| -44% | -$6.22M |
|
10
Outlook Therapeutics
OTLK
$169M
| $5.97M | 1.58% |
+500,000
| New | +$4.04M |
|
|
11
BioCryst Pharmaceuticals
BCRX
$2.48B
| $3.85M | 1.02% |
+758,502
| New | +$4.27M |
|
|
NBP
12
NovaBridge Biosciences American Depositary Shares
NBP
$202M
| $1.41M | 0.37% |
+756,538
| New | +$1.39M |
|
|
13
ADMA Biologics
ADMA
$2.04B
| – | – |
-473,087
| Closed | -$2.14M |
|
|
14
Standard BioTools
LAB
$311M
| – | – |
-7,042,413
| Closed | -$15.6M |
|
|
SCTL
15
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| – | – |
-1,689,768
| Closed | -$592K |
|
Similar funds
BFO
JFGLC
AAM
TP
SCM
NSGL
FMI
RCW
Caligan Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Caligan Partners held 15 positions worth $378M, up 28% from $297M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Caligan Partners deployed $37.2M of net new capital in Q1 2024, opening 4 new positions and adding to 5 existing holdings. Its largest new stake was Enanta Pharmaceuticals: 858,070 shares worth $15M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Y-mAbs Therapeutics, an estimated $6.22M trimmed.
- Caligan Partners's largest Q1 2024 buy was Enanta Pharmaceuticals: 858,070 shares worth $15M.
- Caligan Partners added most to Verona Pharma in Q1 2024, an estimated $19.3M increase.
- Caligan Partners's biggest Q1 2024 reduction was Y-mAbs Therapeutics, cutting an estimated $6.22M.
- Caligan Partners fully exited Standard BioTools in Q1 2024, selling an estimated $15.6M.
- Caligan Partners's ten largest holdings make up 99% of its $378M portfolio in Q1 2024.
- Caligan Partners opened 4 new positions and closed 3 in Q1 2024.
- Caligan Partners's portfolio value rose 28% quarter-over-quarter to $378M.
Based on Caligan Partners's 13F filing for Q1 2024, filed 13 May 2024.